You are viewing the site in preview mode

Skip to main content


Figure 1 | BMC Infectious Diseases

Figure 1

From: Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients

Figure 1

Etest results of a Candida albicans clinical isolate tested against amphotericin B, fluconazole, itraconazole, posaconazole, and voriconazole. Note the lawn of microcolonies inside the ellipses of triazole strips; according to the endpoint rule recommended by the manufacturer, the minimum inhibitory concentration for voriconazole should be 0.008 mg/L, i.e. the first change in growth (black arrow).

Back to article page